Skip to main content
OpenTrials
Completed

NCT Number: NCT04973371

Acceptability and Feasibility of Home-based TB Testing

This study aims to evaluate the utility of home-based point-of-care TB testing for early diagnosis and linkage to care of household contacts of TB patients, addressing the need for active case finding and early detection of infectious TB. The investigators propose an exploratory study to 1) investigate the acceptability and feasibility of home-based TB testing of household contacts using a new portable GeneXpert point-of-care (PoC) platform, and 2) determine the potential impact of such a home-based testing program on early detection of TB disease and linkage-to-care (LTC).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Buffalo City Metro

East London, Eastern Cape, 5217, South Africa

About this study

In 2013, WHO estimated that 3.3 million cases of TB had been missed (undiagnosed or with a significant delay in diagnosis or treatment). "Missed" TB cases are a key driver of TB transmission, with approximately 9 million individuals developing TB globally each year, equivalent to 126 cases per 100,000 population. The overall goal of this proposal is to evaluate the utility of home-based point-of-care TB testing for early diagnosis and linkage to care of household contacts of TB patients, addressing the need for intensive case finding and early detection of infectious TB. Although well-accepted as an effective strategy for boosting HIV diagnosis and treatment rates, until recently home-based testing for TB has been impossible, as there has never existed an effective, mobile PoC technology for rapid diagnosis of TB. With the development of the new GeneXpert® Omni diagnostic platform from Cepheid, home-based TB testing is now possible. Now is the time to study whether home-based testing for TB is feasible, and will contribute to early case detection or improve time-to-treatment rates.

This project has two Specific Aims:

  • To determine the acceptability and feasibility of using point-of-care technology to perform home-based TB testing of household contacts of TB patients, with subaim 1(a): To assess the intent-to-seek care of household contacts symptomatic for TB, and subaim 1(b): To determine the proportion of household contacts symptomatic for TB consenting to be tested (acceptability) and uptake of treatment referrals by those individuals infected with TB within 30 days of testing (feasibility);
  • To describe the outcomes of household contacts screened and tested for TB in their home compared to those screened and referred for testing in a health facility, with subaim 2(a): To describe the barriers and facilitators to clinic follow-up by household contacts symptomatic for TB and provided with referral for TB testing or treatment initiation, and subaim 2(b): To determine whether point-of-care home-based TB testing reduces time-to-treatment initiation.

An exploratory study will be conducted in a high TB prevalence area of Eastern Cape Province, South Africa. Specifically, households of TB patients initiating treatment at one of 6 collaborating clinics will be offered a point-of-care home-based TB test, with referral for immediate treatment when testing positive. In accordance with the South African National TB Management Guidelines (SA-NTMG), all smear positive pulmonary TB (PTB) patients recruited and consented will be asked to provide a list of all household contacts for a household contact investigation. The household contact investigation team will then, in keeping with South African National Department of Health guidelines, seek verbal consent from all household contacts to conduct TB symptom screening. During symptom screening, intent-to-seek care will be assessed for all reported symptoms. If one household member screens positive, then the whole household will be randomized to either the Intervention; home-based GeneXpert point-of-care (PoC) test or Control arm; standard home-based TB symptom screening with referral for testing.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • TB symptomatic household contact of a TB patient
  • Not currently on TB treatment
  • Able to produce a sputum specimen for testing
  • Age ≥18 years
  • Provision of written consent

Exclusion criteria

  • Unable to speak and answer questions in English, Xhosa or Afrikaans
  • Household contact has already been to the facility for TB testing or is already on TB treatment

Treatment and study plan

Home-based point-of-care (POC) TB testing using GeneXpert device + MTB/RIF test

Diagnostic Test

Those who screen positive for TB using the standard 4-question screener will be offered a GeneXpert® [Cepheid, Sunnyvale, CA] MTB/RIF test in their home with referral for clinic-based TB treatment initiation for those who receive a positive MTB/RIF test result.

Primary outcomes

  1. Acceptability of home-based TB testing

    Time frame: Within 1 hour

    ≥ 80% of individuals who screen positive for TB consent to home-based testing using the GeneXpert Platform.

  2. Feasibility of home-based TB testing

    Time frame: Within 1 hour

    ≥80% of households visited having a safe space for sputum production. A safe space for sputum production and collection will be defined as per the South African 2014 National TB Management Guidelines.

  3. Feasibility of home-based TB testing

    Time frame: Immediate upon test completion

    >90% of MTB/Rif tests produce a valid test result

  4. Feasibility of home-based TB testing

    Time frame: Within 4 weeks of diagnosis

    ≥ 80% of household contacts testing positive for TB present at a clinic for care and treatment

Secondary outcomes

  1. Proportion of referral uptake

    Time frame: Within 30 days

    Proportion of household contacts presenting for clinical follow up. (Number of household contacts presenting for clinical follow up / total household contacts referred for clinical follow-up)

  2. Time to clinic presentation

    Time frame: Within 30 days

    Number of days elapsed between date of household contact investigation and date of initial presentation to the clinic.

  3. Time-to-treatment initiation

    Time frame: Within 30 days

    Number of days elapsed between date of household contact investigation and date of TB treatment initiation.

  4. Proportion initiating treatment

    Time frame: Within 30 days

    Number household contacts diagnosed with TB initiating treatment / total household contacts diagnosed with TB

Sponsors and collaborators

Lead sponsor

Foundation for Professional Development (Pty) Ltd

Other

Collaborators

  • Foundation for Innovative New Diagnostics, Switzerland
  • Medical Research Council, South Africa
  • National Institute for Biomedical Imaging and Bioengineering (NIBIB)
  • National Institutes of Health (NIH)
  • University of California, Irvine
  • University of Witwatersrand, South Africa

Registry information

Official study title

Investigating the Acceptability and Feasibility of Home-based TB Testing of Household Contacts Using a New, Mobile Point-of-care Technology

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jul 22, 2021
Registry last updated
Jul 22, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.